This week, the Spanish Society of Digestive Pathology (SEPD) became the most recent organization to announce an updated position statement on the use of biosimilars.
This week, the Spanish Society of Digestive Pathology (SEPD) became the most recent organization to announce an updated position statement on the use of biosimilars.
Published in The Spanish Journal of Gastroenterology,1 the new position statement explains the organization's current thinking on biosimilar usage, extrapolation, and switching. SEPD came to these viewpoints based on the data found by the NOR-SWITCH study, and the new views of the European Crohn’s and Colitis Organization (ECCO) on biosimilars.
SEPD’s new position holds that that:
In addition to SEPD, the American Society of Clinical Oncology (ASCO) also updated its biosimilar position statement in recent days. ASCO’s statement notes that, in terms of the safety and efficacy of biosimilars, postmarket evidence will be key to demonstrating the value of biosimilars to stakeholders. In order to make informed treatment choices, ASCO also emphasizes that prescribers should be consulted before a pharmacist substitutes an interchangeable biosimilar for a reference product. In addition, ASCO discussed the importance of healthcare stakeholders to be able to easily identify products to ensure that patients receive the correct therapy.
In order to limit patient’s out-of-pocket costs, ASCO states that, if a biosimilar is not designated as interchangeable, it could be subject to policies that cover single-source and non-preferred products. “Reasonable compensation, fair and medically appropriate coverage, and transparency of cost will serve to ensure a true value benefit to patients and society and promote access to new and innovative therapies,” notes ASCO.
Reference
1. Arguelles F, Hinojosa J, Mendoza I. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease. Published online March 12, 2018. Rev Esp Enferm Dig. doi: 10.17235/reed.2018.5456/2018.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.